AVITA Medical Announces Medical Education Symposium and Presentation of RECELL System Pivotal Trial Results at U.S. Midwest Region Burn Conference

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL Autologous Cell Harvesting Device (RECELL System) was held at the U.S. Midwest Region Burn Conference in Minneapolis. The symposium was led by Jeffrey Carter, MD, FACS, Medical Director of University Medical Center New Orleans Burn Center and Associate Professor of Surgery at LSU Health New Orleans School of Medicine. Dr. Carter also presented at the conference the results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL System.

The U.S. Food and Drug Administration (FDA) recently approved the RECELL System to treat acute thermal burns in patients 18 years and older. The medical symposium was organized as the first step in training U.S. physicians who had not previously treated patients with the RECELL System in advance of FDA approval in clinical trials or in the Compassionate Use program. The Midwest Region Burn Conference is one of the series of conferences sponsored by the American Burn Association each year.

“The RECELL System allows us to navigate a new course of recovery for people suffering acute burn injuries. The clinical trials using the RECELL System have demonstrated a substantial reduction in the burden of burn care where patients have dramatically reduced donor sites and improved scarring,” said Dr. Carter. “In my own experience at two active burn centers using the RECELL System, patients have also demonstrated significantly reduced length of stays and inspiring outcomes. These kinds of results are exciting, and I am pleased to have the opportunity to share with my peers this innovative product that has enabled us to bring regenerative medicine out of the lab and to the bedside.”

The RECELL System is approved by the FDA to be used at the point of care by licensed healthcare professionals to treat adult patients with acute thermal burn wounds. The RECELL System uses a small amount of a patient’s own skin to prepare Spray-On Skin Cells at the point of care in as little as 30 minutes, providing a new way to treat thermal burns.

The RECELL System can be used alone in the treatment of partial-thickness burns, or in combination with autografting for the treatment of full-thickness burns. A small skin sample is enzymatically and mechanically processed in the RECELL System at the point of care to isolate the skin cells to produce a suspension of Spray-On Skin Cells. The regenerative cell suspension includes keratinocytes, fibroblasts, and melanocytes, which play a critical role in wound healing. The suspension can be sprayed directly on a second degree burn or with an expanded skin graft on a third-degree burn, allowing for broad and even distribution of live cells across the entire wound bed. The RECELL System can be used to prepare enough suspension to treat a wound up to 80 times the size of the donor skin sample, so a skin sample approximately the size of a credit card can be used to treat a wound that covers a patient’s entire back.